Vertran (Betahistine) pills

Instructions for Vertran (Betahistine) pills

English Product Name
Vertran

Release Form
table 16 mg: 30 or 60 pcs.

Description:

White or almost white tablets, round, flat, with beveled edges, with risk on one side.

1 table

• betagistina dihydrochloride 16 mg
• Auxiliaries:
• cellulose microcrystalline 303.619 mg,
• mannitol 108.081 mg, citric acid monohydrate 9.4 mg,
• silicon colloid dioxide 9.4 mg ,
• talc 23.5 mg.

15 pcs. - PVC/PVC blisters/aluminum foil (2) - cardboard packs.
15 pcs. - PVC/PVC blisters/aluminum foil (4) - cardboard packs.

ATX codes
N07CA01 Betahistine

Clinical and pharmacological groups / Group affiliation
Drug Vertran to improve microcirculation of the labyrinth used in pathology of the vestibular apparatus

Active substance
betagistina dihydrochloride

Pharmacotherapeutic group:

Hystamine drug Vertran

Indications Betahistine:

• Meniere Disease;
• Syndromes characterized by dizziness,
• tinnitus and/or progressive hearing loss,
• including internal ear labyrinth water,
• vestibular and labyrinth disorders (including dizziness,
• noise and pain in the ear) ears,
• headache,
• nausea,
• vomiting,
• hearing loss),
• vestibular neuritis,
• maze, benign positional vertigo (including after neurosurgery);
• Vertebrobasil insufficiency,
• post-traumatic encephalopathy,
• atherosclerosis of brain vessels (as part of comprehensive therapy).

Method of application, course and dosage:

One dose - 8-16 mg, intake rate - three times a day.
Treatment is carried out for a long time.

Drug Vertran Interaction:

Antihistamines, when taken simultaneously, reduce the effect of betagistin.

Special Instructions Betahistine:

Use with caution in patients with ulcerative stomach or duodenum disease in the anamnesis, in the II and III trimesters of pregnancy, and in children.
It should be taken into account that the desired clinical effect is achieved after several months of treatment.
In case of dyspeptic symptoms betagistin is recommended to be taken during or after meals.

Child use Betahistine
Use with caution in children.

Nosology Betahistine (ICD codes)
G45.0
Vertebro-Basilar Arterial System Syndrome
H81
Vestibular function violations
H81.0
Menera Disease
H81.1
Good-quality vapor dizziness
H81.2
Vestibular neuronite
H81.3
Other peripheral dizziness
H83.0
Mazyrintit
H83.8
Other specified internal ear diseases
H90
Conductive and neurosensory hearing loss
H93.0
Degenerative and vascular diseases of the ear
H93.1
Tinnitus (subjective)
I67.2
Cerebral atherosclerosis
T90
Effects of head injuries

Pharmacological effect Betahistine:

Synthetic analog of histamine. It acts like histamine, mainly on histamine H1 receptors. Causes the expansion of the precapillaries, in particular, facilitates microcirculation in the maze. Betagistin also regulates the pressure of the endolymphs in the maze and snail, leading to clinical improvement in dizziness of various etiology. Reduces the frequency and intensity of dizziness, reduces tinnitus, helps to improve hearing in cases of its reduction. Increases the tone of the smooth musculature of the bronchial tubes. May cause increased secretion of the gastric juice.